Skip to main content
Equibles
ELTX logo

ELTX · Elicio Therapeutics, Inc. · Investor Relations

Track ELTX — free

Use ELTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ELTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.56 -0.07 (-4.29%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway.”
View the 10-Q filed Nov 5, 2026
Market Cap
$44.16M
Shares
28.31M
Volume · Nov 12 232.82K Avg daily vol (3M) 320.42K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-05 Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-08-13 Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-07-02 Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
2026-06-17 Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
2026-06-15 Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
2026-05-11 Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-03-12 Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
2025-11-13 Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates  In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025.  Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions an

Past events

Date Event Type
2026-09-14 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-06-24 Elicio Therapeutics Virtual KOL Event to Discuss Multiple Complete Responses after ELI-002 7P Treatment Event
2026-06-15 Earnings conference call (announced in 8-K) Earnings call
2026-06-15 June 15th Conference Call Conference
2026-05-14 Bank of America Health Care Conference Conference
2026-03-04 TD Cowen 46th Annual Health Care Conference Conference

Source: https://elicio.com/investors/

Key facts CIK 1601485 CUSIP 28657F103 13F (30d) 44 filings 43 filers Visit website Investor relations